

DRUG UTILIZATION REVIEW BOARD MEETING AGENDA

July 15, 2020
MO HealthNet

Meeting via WebEx only

Meeting number (access code): 289 553 273

Join from a video system or application

Dial 289553273@stateofmo.webex.com

You can also dial 173.243.2.68 and enter your meeting number.

Join by phone

Tap to call in from a mobile device (attendees only)

[1-650-479-3207](tel:1-650-479-3207) Call-in toll number (US/Canada)

Meeting Documents

10:00 – 10:05	Welcome, Announcements and Introductions	Chairperson
10:05 – 10:15	Minutes Review	Discussion/Approval
10:15 – 10:25	Pharmacy Program/ Budget Update	Elizabeth Short
10:25 – 10:35	Review of Prior Authorization Meeting and Public Hearing	Josh Moore

Old Business

10:35 – 10:45	Implementation Schedule – Criteria for Previously Approved Clinical Edits, Step Therapies and PA's	Josh Moore
---------------	--	------------

New Business

10:45 – 11:00	Proposed Actions - New Drug/Product Review (See Website and Attached Summary) <ul style="list-style-type: none">i. Open Accessii. Clinical Edit/Step Therapyiii. PDL Agentsiv. Prior Authorization	Josh Moore
---------------	--	------------

11:00 – 11:45	Clinical Edits <ul style="list-style-type: none">i. Ampyraii. Crysvidaiii. Diacomitiv. Gamifantv. Iron, Injectablevi. Koselugovii. Luxturnaviii. Orilissaix. Oxervatex. Palynziqxi. Parathyroid Hormone & Bone Resorption Suppression Related Agentsxii. Reblozylxiii. Synagisxiv. Tepezzaxv. Tolvaptan	Josh Moore
---------------	--	------------

Preferred Drug List (PDL)

Discussion, Public Hearing and Decision will be held for each edit.

- i. Alpha-Glucosidase Inhibitors
- ii. Amylin Analogs
- iii. Antibiotics, GI, Oral Agents
- iv. Antibiotics, Vaginal Agents
- v. Antihyperuricemic Agents
- vi. Anti-Migraine, Alternative Oral Agents
- vii. Benign Prostatic Hyperplasia Agents
- viii. Biguanides & Combination Agents
- ix. Bile Salt Agents
- x. Bone Ossification Agents
- xi. Cephalosporins
- xii. Colony Stimulating Factors
- xiii. Cryopyrin-Associated Periodic Syndrome (CAPS) Agents
- xiv. DPP-IV Inhibitors & Combination Agents
- xv. Electrolyte Depleters – Phosphate Lowering Agents
- xvi. Electrolyte Depleters – Potassium Lowering Agents
- xvii. Erythropoiesis Stimulating Agents
- xviii. Fluoroquinolones, Oral Agents
- xix. GLP-1 Receptor Agonists & Combination Agents
- xx. Growth Hormones, Somatropin Agents
- xxi. Growth Hormones & Growth Hormone Releasing Factors – Select Agents
- xxii. Hepatitis C Agents
- xxiii. Insulins, Long-Acting
- xxiv. Insulins, Mixed
- xxv. Insulins, Non-Analogs
- xxvi. Insulins, Rapid-Acting
- xxvii. Macrolides
- xxviii. Meglitinides
- xxix. Methotrexate Agents
- xxx. Multiple Sclerosis, Injectable Agents
- xxxi. Multiple Sclerosis, Oral Agents
- xxxii. Penicillins
- xxxiii. Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors & Combination Agents
- xxxiv. Sulfonylureas, 2nd Generation
- xxxv. Targeted Immune Modulators, IL-17A Antibody/IL-17 Receptor Antagonists & IL-23/IL-12 Inhibitors
- xxxvi. Targeted Immune Modulators, IL-6 Receptor Inhibitors
- xxxvii. Targeted Immune Modulators, Janus Kinase (JAK) Inhibitors
- xxxviii. Targeted Immune Modulators, Select Agents
- xxxix. Targeted Immune Modulators, Tumor Necrosis Factor (TNF) Inhibitors
- xl. Tetracyclines
- xli. Thiazolidinediones (TZD) & Combination Agents
- xlii. Thrombocytopenia Agents
- xliii. Urinary Tract Antispasmodics

1:00 – 1:15 **LUNCH**

1:15 – 1:30 **Program Utilization Information – Conduent Update** Katie Wilbers/
Olivia Rush

- i. DUR Report
- ii. Call Center Statistics
- iii. CyberAccess User Statistics
- iv. New Drug Statistics
- v. “Top 25” Drugs by Cost/Claims

1:30 – 1:50 **Other Business**

Informal comments will be accepted from members of the audience at various points in the agenda. Times noted are approximate, Agenda may move more quickly.

Move to close under Section 610.021 Subsection (14), (5) RSMo for proceedings required pursuant to a disciplinary order concerning medical, psychiatric, psychological, or alcoholism or drug dependency diagnosis or treatment of specific licensees.

2:00 – 3:00 **Executive Session**
i. Patient Profile Reviews

NEXT MEETING: October 21, 2020
Department of Natural Resources
1101 Riverside Dr., Jefferson City, MO 65101
Lacharette/Nightingale Rooms